Answers are grounded in this paper and cite their sources.
Bleomycin-induced pulmonary toxicity can have a significant impact on patient outcomes. However, no guidelines for ideal screening and monitoring are available. This paper reviews the literature to identify the best way to monitor and reduce patient risk for bleomycin pulmonary toxicity. We have created evidence-based guidelines to help healthcare professionals identify patient risk factors and provide appropriate assessment and monitoring for patients receiving bleomycin therapy.
No takes yet. Share an insight, caveat, or question.
Shippee et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: